New Two-year Follow-up of Genentech's Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

Genentech announced positive two-year follow-up data from its Phase III STARGLO study, demonstrating a 40% improvement in overall survival for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients treated with Columvi in combination with GemOx compared to Rituxan plus GemOx; median overall survival was not reached in the Columvi arm versus 13.5 months in the Rituxan arm. Furthermore, 89% of patients with a complete response to the Columvi combination were still alive one year post-treatment, highlighting the potential of this off-the-shelf, fixed-duration treatment option for patients who are not candidates for stem cell transplant. The Columvi combination has been approved in over 30 countries and added to the NCCN guidelines as a preferred treatment for second-line DLBCL.

Analysis

Genentech, a member of the Roche Group (RHHBY), has reported compelling two-year follow-up data from the Phase III STARGLO study for Columvi (glofitamab-gxbm) in treating relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients not eligible for autologous stem cell transplant. The study demonstrated a significant 40% improvement in overall survival (OS) for patients receiving Columvi combined with GemOx chemotherapy compared to Rituxan plus GemOx, with median OS not reached in the Columvi arm versus 13.5 months for the control arm after a median follow-up of 24.7 months. Furthermore, among patients achieving a complete response (CR) with the Columvi regimen, 89% were alive and 82% remained in remission one year post-treatment, underscoring the durability of response. The Columvi combination also showed a 59% reduction in the risk of disease progression or death (hazard ratio = 0.41) and more than doubled the CR rate (58.5% vs. 25.3%). These results position Columvi as a much-needed, off-the-shelf, fixed-duration treatment. While the Columvi regimen was associated with a higher rate of adverse events, including generally low-grade cytokine release syndrome, this was in the context of a higher median number of treatment cycles (11 vs. 4) due to better disease control. The drug's approval in over 30 countries and its inclusion as an NCCN category 1 preferred recommendation for second-line DLBCL patients not intended for transplant further validate its clinical utility and potential market penetration.

Key Decisions for Investors

• These robust Phase III STARGLO results significantly strengthen Columvi's clinical profile and are likely to bolster Roche's (RHHBY) oncology franchise, potentially driving market share in the competitive R/R DLBCL landscape.
• Investors should monitor the commercial uptake of Columvi in its approved indications, particularly its adoption as an off-the-shelf option, and track any updates from the SKYGLO study investigating Columvi in earlier lines of DLBCL, which could substantially expand its addressable market.
• While the efficacy is compelling, attention should be paid to the real-world management of Columvi's safety profile, including cytokine release syndrome, as this will influence physician and patient acceptance relative to other treatment modalities.